Your browser doesn't support javascript.
loading
Self-enhancement lateral flow immunoassay for COVID-19 diagnosis.
Ruantip, Sirowan; Pimpitak, Umaporn; Rengpipat, Sirirat; Pasomsub, Ekawat; Seepiban, Channarong; Gajanandana, Oraprapai; Torvorapanit, Pattama; Hirankarn, Nattiya; Jaru-Ampornpan, Peera; Siwamogsatham, Siwaruk; Pongpaibool, Pornanong; Siwamogsatham, Sarawut; Thongchul, Nuttha; Chaiyo, Sudkate.
Afiliação
  • Ruantip S; National Security and Dual-use Technology Center (NSD), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Pimpitak U; Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Bangkok 10330, Thailand.
  • Rengpipat S; Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Bangkok 10330, Thailand.
  • Pasomsub E; Qualified Diagnostic Development Center (QDD), Chulalongkorn University, Bangkok 10330, Thailand.
  • Seepiban C; Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Gajanandana O; Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Torvorapanit P; Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Hirankarn N; Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Jaru-Ampornpan P; Division of Infectious Disease, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Siwamogsatham S; Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Pongpaibool P; Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Siwamogsatham S; National Security and Dual-use Technology Center (NSD), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Thongchul N; National Security and Dual-use Technology Center (NSD), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Chaiyo S; Division of Ambulatory and Hospital Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Sens Actuators B Chem ; 389: 133898, 2023 Aug 15.
Article em En | MEDLINE | ID: mdl-37151731
Equipment-free colorimetric-based lateral flow immunoassay (LFIA) is the most convenient and popular tool for various applications, including diagnostic tools requiring high sensitivity for the detection of pathogens. Thus, improvements and developments of LFIA are constantly being reported. Herein, we enriched the sensitivity of LFIA using the gold enhancement principle, emphasizing needlessly complicated apparatus, only one step for the strip test operation, and typical time incubation (15 min) process. Self-enhanced LFIA was then executed for subsequent flows by overlapping the additionally enhanced pad composed of gold ions and reducing agent on the conjugate pad and the sample pad. Self-enhanced LFIA was performed to detect SARS-CoV-2 antigens in saliva. The obtained result depicted that the achieved sensitivity was up to tenfold compared with that of conventional LFIA by visual measurements. The detection limits of self-enhanced LFIA detecting nucleocapsid protein antigens in the saliva sample was 0.50 and 0.10 ng/mL employed by naked eye detection and calibration curve-based calculation, respectively. When the proposed device was applied to 207 human saliva samples, the diagnostic performance presented a 96.10 % sensitivity and 99.23 % specificity. This self-enhanced LFIA could be implemented in large-scale production and demonstrates higher sensitivity with effortless use, which meets the requirements for point-of-care testing and on-field mass screening.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article